Citations

Clear

1417 citation(s) found for "Li, Simon".

A phase 1 trial of the FACT inhibitor CBL0137 in pediatric patients with relapsed or refractory solid and CNS tumors: A report from the Children’s Oncology Group study PEPN2111.
Shai-Hee, Tyler , Liu, Xiaowei , Yahya, Nawal A., Foster, Jennie Haunani, Fox, Elizabeth , Weigel, Brenda J. , Ziegler, David Simon , Fangusaro, Jason , Tsoli, Maria , Vittorio, Orazio , Minard, Charles G. , Reid, Joel M. , Yahya, Nawal A.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 10051-10051

10.1200/jco.2025.43.16_suppl.10051 Get It

10051 Background: CBL0137 is a novel agent that targets the FAcilitates Chromatin Transcription complex (FACT), a histone chaperone that regulates chromatin remodeling during transcription, replication, and DNA repair. CBL0137 has been shown to have anti-tumor activity in multiple preclinical models of pediatric cancer. We report the phase 1 trial of CBL0137 in children with relapsed or refractory solid tumors including central nervous system (CNS) tumors or lymphoma (NCT04870944). Methods: Patients (age 12 months to 21 years) with relapsed/refractory solid tumors, central nervous system tumors or lymphoma were eligible. In the dose escalation phase, a rolling-six design was used to evaluate CBL0137 administered intravenously (IV) once per week on Days 1 and 8 of a 21-day cycle. The starting dose was 400 mg/m 2 , with escalation to the adult phase 2 dose (RP2D) of 540 mg/m 2 . The maximum tolerated dose (MTD) was determined based on cycle 1 dose limiting toxicity (DLT) using Common Toxicity Criteria for Adverse Events (v5). Pharmacokinetics (PK) and cytokine analyses were performed during cycle 1. Seven additional patients ( < 18 years old) were accrued to a PK expansion cohort at the RP2D. Results: Sixteen patients were enrolled; 14 were evaluable for DLT assessment (12 at 400mg/m 2 [6 in dose escalation and 6 in PK expansion] and 2 at 540mg/m 2 ). The median (range) age was 10 (4-20) years. Diagnoses included high grade glioma (n = 6), osteosarcoma (n = 5), ependymoma (n = 2), neuroblastoma, hepatoblastoma and Burkitt’s lymphoma (1 each). One of 12 evaluable patients treated at 400 mg/m 2 experienced a DLT: Grade 3 photosensitivity. At 540 mg/m 2 , the two evaluable patients both had fever and dose limiting Grade 3 hypotension. Non-dose limiting Grade 3-4 toxicities included anemia, lymphopenia, neutropenia, thrombocytopenia, hypokalemia, anorexia, photosensitivity and fever. For both dose levels, a total of 12 patients were reported to have at least one episode of Grades 1-3 fever and/or Grade 1 cytokine release syndrome (CRS). PK parameters (mean±SD) for CBL0137 (400 mg/m 2 ) were T max = 0.7 ± 0.5 h, C max = 1310 ± 417 ng/mL, and AUC 0-24h = 15300 ± 6790 h·ng/mL. Given the unexpected toxicities of fever, hypotension, and CRS, cytokine samples were collected in patients enrolled in the PK expansion cohort; all had Grade 1 CRS and significantly elevated levels of both IL-10 (adj p = 0.001) and IL-1RA (adj p < 0.001) at 24 hours vs pre-infusion. Conclusions: The RP2D and MTD of CBL0137 in children and adolescents with solid or CNS tumors is 400mg/m 2 IV weekly on Days 1 and 8 of 21-day cycles. CBL0137 leads to immune activation, with cytokine elevation and the possibility of CRS, an unexpected toxicity not previously reported in adults. A Phase 2 cohort in patients with Diffuse Midline Glioma is ongoing and includes further assessment of immune activation. Clinical trial information: NCT04870944 .
Immune checkpoint inhibitor (ICI) reuse after failure of first-line ICI in patients with metastatic dMMR/MSI gastrointestinal cancers: The INFLATE study.
Mercier, Léa , Overman, Michael J. , Alouani, Emily , Dutherage, Marie, Mazard, Thibault , Sclafani, Francesco , Montañá, Javier Ros, Guimbaud, Rosine , Pernot, Simon , Pietrantonio, Filippo , Auclin, Édouard , Hollebecque, Antoine , Lonardi, Sara , Sinicrope, Frank A. , Tougeron, David , Turpin, Anthony , Jayachandran, Priya , Palmieri, Lola‐Jade , Taı̈eb, Julien

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3569-3569

10.1200/jco.2025.43.16_suppl.3569 Get It

3569 Background: Immune checkpoint inhibitors (ICIs) are a standard treatment for gastrointestinal (GI) cancers with mismatch repair deficiency (dMMR) or microsatellite instability (MSI). However, around 50% of patients develop resistance to ICIs, during treatment or after discontinuation. In these patients, the efficacy of reuse an ICI in patients progressing during a previous ICI (rechallenge), or in patients who progressed after discontinuation (reintroduction), remains unknown. The INFLATE study evaluates the efficacy of ICI reuse in patients who progressed on or after discontinuing ICI. Methods: This is a multicenter international retrospective study from the IMMUNODIG cohort, including patients from 34 centers in France, the United States, Italy, Belgium and Spain. All patients received ICI for dMMR/MSI GI cancer. We analyzed patients who had progressed following initial ICI (ICI-1) and subsequently received a rechallenge or a reintroduction with ICI (ICI-2), either monotherapy (mono-ICI) or biotherapy (bi-ICI). Results: A total of 77 patients were included, receiving bi-ICI (N = 34) or mono-ICI (N = 43) during ICI-2. The majority (76%) had a metastatic colorectal cancer. The reason for discontinuing ICI-1 was disease progression in 53% of cases, end of treatment in 15%, toxicity in 5% and other reasons in 26%. Patients who discontinued ICI-1 due to progression received MONO-ICI-2 in 29% of cases and BI-ICI-2 in 71%, whereas those who stopped for other reasons received MONO-ICI-2 in 86% and BI-ICI-2 in 14% of cases. Efficacy results are shown in Table 1. The ORR and DCR were 26% and 79% with MONO-ICI-2, and 16% and 71% with BI-ICI-2. Among patients who discontinued ICI-1 due to progression, BI-ICI-2 (N = 29) achieved an ORR and DCR of 8% and 65%, with a median PFS of 5.5 months (95%CI 4.07-10.4). These outcomes were 17%, 67%, and 3.7 months (95%CI 2.37-NA), respectively, with MONO-ICI-2 (N = 12). For patients who discontinued ICI-1 for reasons other than progression, BI-ICI-2 (N = 5) achieved an ORR and DCR of 60% and 100%, with a median PFS not reached (95%CI 11.5-NR), while MONO-ICI-2 (N = 31) achieved 29%, 82%, and 14.2 months (95%CI 11.2–NR), respectively. Conclusions: This is the first multicenter real-world study evaluating ICI reuse in dMMR/MSI GI cancers. In patients who discontinued ICI for reasons other than progression, reintroduction of ICI therapy upon progression achieves tumor control in 85% of cases. In cases of progression on mono-ICI, Bi-ICI re-challenge achieve tumor control in two-thirds of cases and might be to consider in some patients. ORR % DCR % PFS median (95%CI) OS median (95%CI) Overall N=77 21 76 7.65 months(5.5–11.5) 27.6 months(22.2–55.7) Discontinued ICI-1 due to Progression N=41 11 68 5.03 months(3.7–8.05) 26.7 months(21.1–NR) Discontinued ICI-1 for Other Reasons N=36 33 85 14.22 months(11.24–NR) 27.6 months(22.2–NR)
Impact of germline vs somatic BRCA mutation status on the efficacy of rucaparib vs physician’s choice in the TRITON3 study of patients with metastatic castration-resistant prostate cancer.
Chowdhury, Simon, Fizazi, Karim , Saez, María-Isabel, Redfern, Charles H., Benjelloun, Ali, Burke, John M. , Campbell, David , Fléchon, Aude , Malik, Zafar, Reid, Alison Helen, Santis, Maria De , Koshkin, Vadim S. , Rosenbaum, Eli, Connor, Christy, Peynado, Merrissa, Ryan, Charles J. , Bryce, Alan H. , Benjelloun, Ali, Reid, Alison H.M., Graff, Julie Nicole , Pinto, Álvaro , Fontana, Elisa

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 5060-5060

10.1200/jco.2025.43.16_suppl.5060 Get It

5060 Background: Rucaparib significantly improved radiographic progression-free survival (rPFS) in men with BRCA-mutated chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) vs a control arm of physician’s choice of therapy (docetaxel or androgen-receptor pathway inhibitor [ARPI] therapy: abiraterone acetate or enzalutamide) in the randomized, multicenter, open-label, phase 3 TRITON3 (NCT02975934) study. Herein, we conducted an analysis to determine the impact of germline vs somatic mutation status on the efficacy of rucaparib. Methods: Patients were randomized 2:1 to receive rucaparib 600 mg BID or physician’s choice of docetaxel or ARPI following progression while on 1 prior second-generation ARPI in any setting. The primary endpoint was rPFS. Color Health did genetic testing. Treatment-emergent adverse events (TEAEs) were reported for the BRCA subgroup. Results: In the rucaparib arm, 201/270 patients had BRCA mutations, and in the physician’s choice arm, 101/135 patients had BRCA mutations. Of patients with BRCA mutations: in the rucaparib arm, 80/201 (40%) were germline and 116/201 (58%) were somatic with 5/201 (2%) BRCA mutation status unknown, while in the physician’s choice arm, 39/101 (39%) were germline and 48/101 (48%) were somatic with 14/101 (14%) BRCA mutation status unknown. rPFS was significantly improved with rucaparib treatment vs physician’s choice in both the germline and somatic mutation groups (germline: HR, 0.52 [95% CI, 0.32–0.84]; somatic: HR, 0.38 [95% CI, 0.25–0.59]). Incidence rates of TEAEs were similar overall between patients with germline and somatic BRCA mutations in both arms. Conclusions: Rucaparib improves progression-free survival for patients with mCRPC with either germline or somatic BRCA mutations with a manageable safety profile. These data support the use of rucaparib as a beneficial treatment option for patients with BRCA-mutated mCRPC with germline or somatic mutations. Clinical trial information: NCT02975934 .
Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
Shroff, Rachna T. , Carneiro, Benedito A. , Sahai, Vaibhav , Ploquin, Anne , Hiret, Sandrine , Percent, Ivor , Pernot, Simon , Kavan, Petr , Mulcahy, Mary F. , Mazar, Andrew P. , Fine, Gil D., Sahai, Vaibhav , Mahalingam, Devalingam , Ji, Yan , Coveler, Andrew L. , Cervantes, Andrés , LoConte, Noelle K. , Lopez, Charles D. , Carr, Ryan M , Giles, Francis Joseph , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 4006-4006

10.1200/jco.2025.43.16_suppl.4006 Get It

4006 Background: Elraglusib (9-ING-41) is a first-in-class inhibitor of GSK-3ß, which may mediate drug resistance, EMT, and damaged DNA and tumor immune response in advanced cancer. In pancreatic cancer models in mice, elraglusib combined with chemotherapy enhanced anti-tumor effects and survival. In a single-arm clinical study, elraglusib/GnP showed antitumor activity and prolonged survival in pts with mPDAC. Methods: Pts with previously untreated mPDAC were randomized 2:1 to GnP plus elraglusib 9.3 mg/kg IV once weekly or GnP in an open-label phase 2 study. The primary endpoint was 1-yr OS in the primary analysis set. Upon study completion, mOS will be the primary endpoint once survival distributions are compared after the 12-month follow-up using log-rank analysis. Secondary endpoints included DCR, ORR, mPFS, and TEAEs/TRAEs. The planned sample size was 207 evaluable pts (130 for elraglusib/GnP and 77 for GnP), assuming 1-yr OS of 55% with elraglusib/GnP and 35% with GnP to achieve 80% power with a chi-square test at a 2-sided 5% α. For OS, nonparametric log-rank test was used with statistical significance at p-value < 0.048. Cytokine/chemokine correlative biomarker assays were performed. The study completed enrollment in February 2024. Results: As of November 15, 2024 (preliminary data cut-off date), the primary analysis set included 155 pts in the elraglusib/GnP arm and 78 pts in the GnP arm, with 52.8% males and 57.5% ECOG PS 1. Median (range) CA 19-9 levels were 1568 U/mL (1 to 381,904 U/mL) in the elraglusib/GnP arm and 1590 U/mL (2 to 501,000 IU/mL) in the GnP arm. The 1-yr OS rate was 43.6% with elraglusib/GnP vs 22.5% with GnP (z-test p = 0.002); the mOS was 9.3 mo with elraglusib/GnP vs 7.2 mo with GnP (HR, 0.63; log rank p = 0.016; see Table). 38.1% of pts on elraglusib/GnP and 19.2% on GnP are censored, with the majority at > 10 months OS. Several biomarkers appear to be predictive for OS including IFNβ and PD-L1. The most common TRAE with elraglusib/GnP was grade 1-2 transient visual impairment in > 60% of patients (vs 9% with GnP). Grade ≥3 TEAEs occurred in 89.7% of pts on elraglusib/GnP and 80.8% on GnP. Most common grade ≥3 TEAEs with elraglusib/GnP (vs GnP) were neutropenia 51.6% (vs 29.5%), anemia 24.5% (vs 29.5%), and fatigue 16.1% (vs 5.1%). Conclusions: The preliminary results showed a statistically significant benefit for 1-yr OS and mOS and favorable trends for ORR and DCR with elraglusib/GnP over GnP, with manageable safety profile. The mOS for GnP is lower relative to MPACT and NAPOLI-3 but comparable to recent real-world meta-analyses, explained by advanced disease burden and higher mortality rate in the first 4 months in our study. Topline analysis (April 2025) and correlative biomarker analysis predictive for OS will be presented. Clinical trial information: NCT03678883 . Preliminary efficacy results. Elraglusib/GnPn=155 GnPn=78 1-year OS, %z-test p=0.002 43.6 22.5 mOS, moHR=0.63; log-rank p=0.016 9.3 7.2 Events, n (%) 96 (61.9) 63 (80.8) mPFS, moHR=0.91; p=NS 5.6 4.9 Events, n (%) 128 (82.6) 70 (89.7) DCR, % 42.6 33.3 ORR, n (%) 43 (27.7) 16 (20.5)
Arthroscopic Versus Open Iliopsoas Release After Total Hip Arthroplasty
Holliday, Charles L. , Simon, Karissa N. , Trousdale, Robert T., Levy, Bruce A. , Hevesi, Mario , Hevesi, Mario , Trousdale, Robert T. , Taunton, Michael J.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | May 27, 2025 | Volume: 7 | Issue: 4 | Pages: No page available

10.1016/j.asmr.2025.101190 | PMID 40980242 Get It

Purpose To evaluate the differences in clinical outcomes and complication rates between open and arthroscopic iliopsoas (IP) tenotomy between 1998 and 2023 at our institution. Methods Patients who underwent arthroscopic iliopsoas fractional lengthening (IPFL) or open tenotomy for IP tendinitis following total hip arthroplasty (THA) between 1988 and 2023 were identified. Patients were excluded if they underwent revision IP tendon release, had additional concomitant procedures, or had less than a 24‐month postoperative follow‐up. Patient records were reviewed, and patient‐reported outcomes were collected via electronic survey. Results Fifty‐two patients (36 arthroscopic, 16 open) were followed for an average of 68.7 (24.0‐203.7) months. Overall surgery satisfaction was 7.9 (scale 0‐10) following arthroscopic IPFL and 6.0 following open tenotomy ( P = .178). Eighty‐six percent of patients reported improvement in their anterior groin pain following arthroscopic IPFL, compared to 45% following open tenotomy ( P = .065). In the arthroscopic cohort, 64% reported improved hip flexion strength, compared to 36% in the open cohort ( P = .158). Visual analog scale for pain at rest was lower following arthroscopic IPFL (1.1 ± 2.2 vs 3.3 ± 3.2, P = .0092), while pain with use did not differ between cohorts (3.1 ± 1.3 vs 2.6 ± 1.1, P = .786). There were no differences in postoperative Tegner (3.1 ± 1.3 vs 2.6 ± 1.1, P = .302), modified Harris Hip Score (77.0 ± 19.0 vs 69.2 ± 26.9, P = .073), or Single Assessment Numeric Evaluation (70.9 ± 28.7 vs 66.7 ± 31.8, P = .571) scores between arthroscopic and open cohorts. Revision THA rates did not differ following arthroscopic or open procedures (8.3% vs 25%, P = .104). Conclusions Patients have improved pain at rest following arthroscopic IPFL when compared to open tenotomy for IP tendinitis following THA. Overall complication and reoperation rates were low for both techniques. Level of Evidence Level III, retrospective cohort study.
Improving Preparatory Materials for the Pediatric Infectious Diseases Initial Certifying Exam: A Targeted Needs Assessment
Sattler, Matthew M , Ristagno, Elizabeth H. , Boguniewicz, Juri , Fatemi, Yasaman , Jamal, Hassan H. , Vidal, Diego A Cruz , Boguniewicz, Juri , Jamal, Hassan, Parzen-Johnson, Simon

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | May 25, 2025 | Volume: 14 | Issue: 6 | Pages: No page available

10.1093/jpids/piaf048 | PMID 40413637 Get It

Abstract We conducted a national survey of current pediatric infectious diseases (PID) fellows and PID fellowship graduates from the past 10 years to assess satisfaction with existing PID initial certifying exam preparatory materials. Satisfaction with existing resources was low. The most desired new resource was additional board-style questions.
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage
Collaborators, GBD 2021 Global Subarachnoid Hemorrhage Risk Factors, Rautalin, Ilari, Stark, Benjamin, Johnson, Catherine O., Kaprio, Jaakko , Korja, Miikka, Krishnamurthi, Rita , Nair, Balakrishnan , Vergouwen, Mervyn D. I. , Abdelkader, Atef , Abdullahi, Auwal , Abualruz, Hasan , Abukhadijah, Hana J , Adamu, Lawan Hassan, Adegboye, Oyelola A. , Adzigbli, Leticia Akua, Agyemang‐Duah, Williams , Ahinkorah, Bright Opoku, Ahmad, Aqeel , Ahmad, Danish , Ahmadzade, Amir Mahmoud , Akkaif, Mohammed Ahmed , Ali, Mohammed Usman, Alif, Sheikh Mohammad , Alimohamadi, Yousef, Alsabri, Mohammed , Altaf, Awais , Alvis‐Guzmán, Nelson , Alwafi, Hassan , Al‐Wardat, Mohammad , Alyahya, Mohammad S. , Amin, Tarek Tawfik , Amindarolzarbi, Alireza , Amusa, Ganiyu , Angappan, Dhanalakshmi , Anuoluwa, Boluwatife Stephen, Anwar, Saleha, Anyasodor, Anayochukwu Edward , Apostol, Geminn Louis Carace, Areda, Demelash, Artamonov, Anton A, Artanti, Kurnia Dwi , Ashemo, Mubarek Yesse , Athar, Mohammad , Aujayeb, Avinash , Awotidebe, Adedapo Wasiu , Azadnajafabad, Sina , Aziz, Shahkaar , Bagheri, Nasser , Taqanaki, Pegah Bahrami , Bahramian, Saeed , Bai, Ruhai , Baig, Atif Amin , Baltatu, Ovidiu Constantin , Bam, Kiran, Barker‐Collo, Suzanne , Bärnighausen, Till , Bastan, Mohammad‐Mahdi , Basu, Sanjay , Bell, Shelly L, Benseñor, Isabela M , Berhie, Alemshet Yirga , Bhagavathula, Akshaya Srikanth , Bhaskar, Sonu , Bhat, Ajay Nagesh, Bhat, Vivek , Birhan, Mekuriaw Mesfin , Borhany, Hamed, Breitner, Susanne , Bulamu, Norma B. , Butt, Zahid A , Cabral, Lucas Scotta , Santos, Florentino Luciano Caetano dos , Cámera, Luis Alberto , Capodici, Angelo , Chadwick, Joshua , Chakraborty, Promit Ananyo , Chanie, Gashaw Sisay , Chattu, Vijay Kumar , Chi, Gerald, Chichagi, Fatemeh , Columbus, Alyssa , Criqui, Michael H, Ohadi, Mohammad Amin Dabbagh , Dadras, Omid , Dalli, Lachlan L. , Debopadhaya, Shayom , Dervišević, Emina , Devanbu, Vinoth Gnana Chellaiyan, Dewan, Syed Masudur Rahman , Dhane, Amol S. , Chi, Thanh, Phuong, Thao Huynh, Dohare, Sushil , Докова, Клара , Dowou, Robert Kokou , Dsouza, Haneil Larson , Dutta, Siddhartha , Dziedzic, Arkadiusz , E’mar, Abdel Rahman, Edvardsson, David , Efendi, Ferry, Nahas, Nevine El , Elgendy, Islam Y. , Eltaha, Chadi, Emeto, Theophilus I. , Fakhradiyev, Ildar , Faris, Pawan , Fauk, Nelsensius Klau , Fazylov, Timur, Fekadu, Ginenus , Fetensa, Getahun, Fischer, Florian, Foschi, Matteo , Fridayani, Ni Kadek Yuni, Gaipov, Abduzhappar , Gajjar, Avi A. , Ganesan, Balasankar , Gebregergis, Miglas Welay, Gebremeskel, Teferi Gebru , Getie, Molla , Ghadirian, Fataneh , Ghasemzadeh, Afsaneh , Gholamalizadeh, Maryam , Gil, Artyom , Goleij, Pouya , Goulart, Alessandra C. , Goulart, Bárbara Niegia Garcia de , Guan, Shi‐Yang , Gupta, Sapna , Habibzadeh, Farrokh , Hadi, Najah R, Hankey, Graeme J. , Harlianto, Netanja I. , Hasani, Hamidreza, Hasnain, Md Saquib , Haubold, Johannes , Havmoeller, Rasmus, Hay, Simon I , Hbid, Youssef , Heidari, Golnaz , Hiraike, Yuta, Hoan, Nguyen Quoc , Hosseinzadeh, Mehdi , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ikiroma, Adalia , Isola, Gaetano , Iwagami, Masao , Jacob, Louis, Jain, Akhil, Jakovljević, Mihajlo , Jatau, Abubakar Ibrahim , Jawaid, Talha, Jayapal, Sathish Kumar , Jonas, Jost B, Joseph, Nitin , Jürisson, Mikk , Kadashetti, Vidya, Kalani, Rizwan, Kamireddy, Arun , Kandel, Himal , Behnagh, Arman Karimi , Kashoo, Faizan , Kayode, Gbenga A , Kazemi, Foad , Khader, Yousef , Khaing, Inn Kynn , Khan, Fayaz Ahmad , Khan, Mohammad Jobair , Kashani, Hamid Reza Khayat , Khosla, Atulya Aman , Kim, Kwanghyun , Kim, Yun Jin , Korzh, Oleksii , Krishan, Kewal , Krishna, Varun, Krishnamoorthy, Vijay , Kuddus, Mohammed , Kulimbet, Mukhtar , Lahariya, Chandrakant, Lai, Daphne Teck Ching , Lai, Hanpeng , Laksono, Tri, Lallukka, Tea , Latifinaibin, Kaveh, Le, Nhi Huu Hanh, Le, Thao T. , Lee, Munjae , Lee, Yo Han , Lenzi, Jacopo , Leonardi, Matilde, Li, Ming‐Chieh , Li, Xiaopan , Lim, Stephen S , Lin, Jialing , Saute, Ricardo Lutzky , Malik, Ahmad Azam , Marateb, Hamid Reza , Maroufi, Seyed Farzad , Maugeri, Andrea , McPhail, Steven , Mehndiratta, Man Mohan, Mestrovic, Tomislav, Mettananda, Chamila Dinushi Kukulege , Miazgowski, Tomasz , Minervini, Giuseppe , Mithra, Prasanna , Mohamed, Abdalla Z. , Mohammad, Ameen Mosa , Mohammed, Shafiu , Moni, Mohammad Ali , Moradi, Yousef, Moraga, Paula , Morawska, Lídia , Munjal, Kavita , Murray, Christopher J L , Nagarajan, Ahamarshan Jayaraman , Naik, Ganesh R. , Najdaghi, Soroush , Davani, Delaram Narimani , DELETE-ME, Nawsherwan, Nazri-Panjaki, Athare , Negoi, Ruxandra Irina , Nematollahi, Soroush , Nguyen, Hau Thi Hien, Nguyen, Hau Thi Hien, Nguyen, Phat Tuan , Nguyễn, Văn Thành , Niazi, Robina Khan, Nikoobar, Ali , Sá, Antonio Tolentino Nogueira de , Nomura, Shuhei , Nzoputam, Chimezie Igwegbe , Oancea, Bogdan , Ojo-Akosile, Tolulope R, Oliveira, Gláucia Maria Moraes de , Olorukooba, Abdulhakeem Abayomi , Osuagwu, Uchechukwu Levi , Ouyahia, Amel, A, Mahesh Padukudru P, Panagiotakos, Demosthenes B. , Parikh, Romil R., Park, Seoyeon , Pedersini, Paolo , Peprah, Emmanuel , Perico, Norberto, Petermann-Rocha, Fanny Emily, Plotnikov, Evgenii , Полибин, Р. В. , Postma, Maarten J. , Prasad, Manya , Qian, Gangzhen , Rahmanian, Mohammad , Rajaa, Sathish , Rajput, Prashant , Ramadan, Mahmoud M. , Rane, Amey, Rashidi, Mohammad‐Mahdi , Razo, Christian , Reddy, Murali Mohan Rama Krishna, Remuzzi, Giuseppe, Rezaei, Negar , Rezaeian, Mohsen , Rocha, Hermano Alexandre Lima , Rodriguez, Jefferson Antonio Buendia, Roever, Leonardo , Romoli, Michele, Romozzi, Marina, Roy, Nitai , Saddik, Basema Ahmad, Sahoo, Pragyan Monalisa , Salaroli, Luciane Bresciani , Samuel, Vijaya Paul, Samy, Abdallah M , Santric-Milicevic, Milena M., Saravanan, Aswini, Schlaich, Markus P. , Sethi, Yashendra , Seylani, Allen, Shaaban, Ahmed Nabil , Shafie, Mahan , Shaikh, Summaiya Zareen , Shamsutdinova, Alfiya, Sharifan, Amin , Rad, Javad Sharifi, Sharma, Vishal, Shashamo, Bereket Beyene , Shetty, Premalatha K, Shigematsu, Mika, Shorofi, Seyed Afshin, Singh, Paramdeep , Singh, Puneetpal , Singh, Surjit , Sobia, Farrukh , Solanki, Shipra, Soraneh, Soroush , Spartalis, Michael, Srinivasamurthy, Suresh Kumar , Stanikzai, Muhammad Haroon , Sun, Zhong , Swain, Chandan Kumar , Damavandi, Payam Tabaee , Tabatabaeizadeh, Seyed-Amir, Tabche, Celine , Taiba, Jabeen , Tamuzi, Jacques Lukenze , Tan, Ker‐Kan , Teramoto, Masayuki , Thakur, Ramna, Thankappan, Kavumpurathu Raman , Thayakaran, Rasiah , Thirunavukkarasu, Sathish, Ticoalu, Jansje Henny Vera, Tiwari, Krishna Raj , Tonelli, Marcello , Topór-Mądry, Roman , Tovani-Palone, Marcos Roberto Roberto, Tran, Jasmine, Tran, Thang Huu , Duc, Nguyen Tran Minh , Truelsen, Thomas Clement, Unim, Brigid, Vahdati, Sanaz, Vaithinathan, Asokan Govindaraj , Eynde, Jef Van den , Vladimirov, Sergey Konstantinovitch , Waheed, Yasir, Wahood, Waseem , Walde, Mandaras Tariku, Wang, Yanzhong , Wickramasinghe, Nuwan Darshana , Wolfe, Charles D. A., Wubie, Yihun Miskir, Xiao, Hong , Xu, Xiaoyue , Yano, Yuichiro , Yarahmadi, Amir , Ye, Pengpeng, Yon, Dong Keon , Zanghì, Aurora , Zare, Iman, Zastrozhin, Michael, Zhang, Zhi-Jiang , Zhang, Zhiqiang , Zhang, Zhiqiang, Zhao, Hanqing , Zhou, Shang Cheng, Zhumagaliuly, Abzal , Zia, Hafsa, Roth, Gregory A., Topór‐Mądry, Roman , Oliveira, Arão Belitardo , Rahim, Fakher , Saddik, Basema , Waheed, Yasir , Liu, Xuefeng , Zhang, Yunquan , Ozair, Ahmad , Buendía, Jefferson Antonio , Korja, Miikka , Baig, Atif Amin , Shanawaz, Mohd , Elgendy, Islam Y , Hankey, Graeme J , Alif, Sheikh M , Rezaei, Negar , Bhagavathula, Akshaya Srikanth , Van den Eynde, Jef , Ozair, Ahmad , Collaborators, GBD 2021 Global Subarachnoid Hemorrhage Risk Factors, Rautalin, Ilari Matias , Volovici, Victor , Ranta, Annemarei , Rinkel, Gabriël J.E. , Abate, Yohannes Habtegiorgis, Abbastabar, Hedayat , Abd-Allah, Foad , Abdi, Parsa , Abdollahi, Arash , Abiodun, Olugbenga Olusola , Aboagye, Richard Gyan , Abouzid, Mohamed , Abtahi, Dariush , Abu‐Rumeileh, Samir , Abualhasan, Ahmed , Abu‐Zaid, Ahmed , Addo, Isaac Yeboah , Adedoyin, Rufus Adesoji , Adra, Saryia , Ahinkorah, Bright Opoku , Ahmed, Ali , Ahmed, Haroon , Ahmed, Syed Anees , Aji, Budi , Al‐Ajlouni, Yazan A. , Al‐Aly, Ziyad , ALBashtawy, Mohammed , Aljunid, Syed Mohamed , Alomari, Mahmoud A. , Alrawashdeh, Ahmad , Alsabri, Mohammed A., Salman, Rustam Al‐Shahi , Al‐Tammemi, Ala’a B. , Al‐Worafi, Yaser Mohammed , Aly, Hany Z. , Alzoubi, Karem Hasan , Amani, Reza, Anderlini, Deanna , Anil, Abhishek , Arabloo, Jalal , Ärnlöv, Johan , Arumugam, Ashokan , Aryan, Zahra , Jafarabadi, Mohammad Asghari , Ashraf, Tahira , Athari, Seyyed Shamsadin , Azzam, Ahmed Y , Babu, Giridhara R. , Bako, Abdulaziz Tijjani , Banach, Maciej , Bandyopadhyay, Soham , Banik, Biswajit , Bardhan, Mainak , Barqawi, Hiba Jawdat , Barua, Lingkan , Beyene, Kebede Abera , Bhat, Vivek, Bhatti, Gurjit Kaur , Bhatti, Jasvinder Singh , Bijani, Ali , Bikbov, Boris , Birhanu, Mulugeta Molla , Bitra, Veera Raghavulu , Boloor, Archith , Brenner, Hermann , Bugiardini, Raffaele , Călina, Daniela Cornelia , Campos, Luciana Aparecida , Campos‐Nonato, Ismael , Carvalho, Félix , Castañeda-Orjuela, Carlos A , Catapano, Alberico Luigi , Cegolon, Luca , Chakraborty, Chiranjib , Chakraborty, Sandip , Chandika, Rama Mohan , Chaudhary, Anis Ahmad , Chi, Gerald , Ching, Patrick R , Chopra, Hitesh , Choudhari, Sonali Gajanan , Chowdhury, E. , Chu, Dinh‐Toi , Chung, Sheng‐Chia , Silva, Alanna Gomes da , Dai, Xiaochen , Dalal, Koustuv , D’Amico, Emanuele , Dashti, Mohsen , Davletov, Kairat , Cruz-Góngora, Vanessa Vianey De la , Delgado‐Enciso, Iván , Devanbu, Vinoth Gnana Chellaiyan, Dibas, Mahmoud , Doheim, Mohamed Fahmy , Dongarwar, Deepa , D’Oria, Mario , Doshi, Ojas Prakashbhai , Doshi, Rajkumar , Efendi, Defi , Efendi, Ferry , Elhadi, Muhammed , Eltahir, Mohd. Elmagzoub , Fabin, Natalia , Fagbamigbe, Adeniyi Francis , Fahim, Ayesha , Fares, Jawad , Ferreira, Nuno Bravo , Gandhi, Aravind P. , Garg, Ravindra Kumar , Gebrehiwot, Mesfin , Ghadimi, Delaram J. , Ghahramani, Sulmaz , Ghazy, Ramy Mohamed , Ghozy, Sherief , Gilani, Jaleed Ahmed , Gnedovskaya, Elena V. , Hadei, Mostafa , Hamidi, Samer , Hanifi, Nasrin , Haro, Josep María , Hasan, Faizul , Tabatabaei, Mahgol Sadat Hassan Zadeh , Heidari, Mohammad , Hemmati, Mehdi , Holla, Ramesh , Hostiuc, Sorin , Huang, Junjie , Huynh, Hong-Han , Ikeda, Nayu , Ilaghi, Mehran , Ilesanmi, Olayinka Stephen , Ilić, Irena , Ilić, Milena , Islam, Md. Rabiul , Ismail, Nahlah Elkudssiah , Iso, Hiroyasu , Jafarzadeh, Abdollah , Jairoun, Ammar Abdulrahman , Kalani, Rizwan, Kamal, Vineet Kumar , Kanchan, Tanuj , Karami, Jafar , Karaye, Ibraheem M. , Karimi, Yeganeh , Kesse‐Guyot, Emmanuelle , Khan, Fayaz, Khatatbeh, Haitham , Khatatbeh, Moawiah Mohammad , Kheirallah, Khalid Ahmed , Khidri, Feriha Fatima , Khormali, Moein , Kısa, Adnan , Kısa, Sezer , Kivimäki, Mika , Kolahi, Ali‐Asghar , Kompani, Farzad , Kostev, Karel , Kothari, Nikhil , Kunutsor, Setor K. , Kurniasari, Maria Dyah , Kusuma, Dian Palupi , Kytö, Ville , Vecchia, Carlo La , Lahariya, Chandrakant , Latief, Kamaluddin , Lee, Seung Won , Lee, Wei‐Chen , Leonardi, Matilde, Liu, Xuefeng , Lohner, Valerie , Lorenzovici, László , Lotufo, Paulo A. , Lucchetti, Giancarlo , Lusk, Jay B. , Amin, Hawraz Ibrahim M. , Malhotra, Armaan Kush , Malhotra, Kashish , Malta, Déborah Carvalho , Mansournia, Mohammad Alì , Mantovani, LG , Manu, Emmanuel, Marino, Mirko , Martínez, Ramón , Martini, Santi , Martorell, Miquel , Marzo, Roy Rillera , Mathangasinghe, Yasith , Mathews, Elezebeth , Mehmood, Asim , Mehrabani-Zeinabad, Kamran , Menezes, Ritesh G. , Meo, Sultan A , Meretoja, Atte , Meštrović, Tomislav , Sá, Ana Carolina Micheletti Gomide Nogueira de , Minh, Le Huu Nhat , Mirică, Andreea , Мirrakhimov, Erkin М , Mirza‐Aghazadeh‐Attari, Mohammad , Mishra, Ajay Kumar , Mohamed, Ahmed Ismail , Mohammadi, Soheil , Mohammadian-Hafshejani, Abdollah , Mokdad, Ali H. , Molinaro, Sabrina , Momani, Shaher , Ghalibaf, AmirAli Moodi , Moradi, Maryam , Msherghi, Ahmed A.A. , Ansari, Noureddin Nakhostin , Nargus, Shumaila , Natto, Zuhair S. , Nauman, Javaid , DELETE-ME, Nawsherwan, Nayak, Vinod C , Newton, Charles R. , Nigatu, Yeshambel T. , Noubiap, Jean Jacques , Nugen, Fred , Oduro, Michael Safo , Okati‐Aliabad, Hassan , Okeke, Sylvester Reuben , Okekunle, Akinkunmi Paul , Olagunju, Andrew T , Olaiya, Muideen Tunbosun , Olufadewa, Isaac Iyinoluwa , Ornello, Raffaele , Ortiz‐Prado, Esteban , Ouyahia, Amel , Owolabi, Mayowa , Padrón‐Monedero, Alicia , Padubidri, Jagadish Rao , Panos, Leonidas D , Pantazopoulos, Ioannis N. , Parikh, Romil R., Patel, Jay , Patel, Urvish , Patoulias, Dimitrios , Pereira, Gavin F , Perianayagam, Arokiasamy , Perna, Simone , Petermann‐Rocha, Fanny , Philip, Anil K. , Пирадов, М. А. , Pradhan, Jalandhar , Puvvula, Jagadeesh , Qasim, Nameer Hashim , Raggi, Alberto , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Rahmani, Amir Masoud , Sanati, Ali Rajabpour , Ramasamy, Shakthi Kumaran , Ramazanu, Sheena , Rathish, Devarajan , Rawaf, Salman , Redwan, Elrashdy M , Remuzzi, Giuseppe , Romoli, Michele, Romozzi, Marina , Ross, Allen Guy , Rout, Himanshu Sekhar , Roy, Priyanka , Saad, Aly M A , Saadatian, Zahra , Sabour, Siamak , Sacco, Simona , Sadeghi, Erfan , Saeed, Usman, Sharif‐Askari, Fatemeh Saheb , Sahebkar, Amirhossein , Sajib, Md Refat Uz Zaman , Saleh, Mohamed A. , Samodra, Yoseph Leonardo , MİLİCEVİC, Milena Santric, Saravanan, Aswini , Sarkar, Tanmay, Sarode, Sachin Chakradhar , Sartorius, Benn , Satpathy, Maheswar , Schneider, Ione Jayce Ceola , Schuermans, Art , Selvaraj, Siddharthan , Senthilkumaran, Subramanian , Sepanlou, Sadaf Ghajarieh , Shahwan, Moyad Jamal , Shamim, Muhammad Aaqib , Shamsi, Anas , Shannawaz, Mohammed , Rad, Javad Sharifi, Sharma, Vishal , Shittu, Aminu , Shiue, Ivy , Shlobin, Nathan A. , Siddig, Emmanuel Edwar , Spartalis, Michael , Stanaway, Jeffrey D , Starodubova, Antonina Vladimirovna , Szarpak, Łukasz , Tabatabaeizadeh, Seyed‐Amir , Tabatabaeizadeh, Seyed-Amir, Talaat, Iman Mamdouh , Temsah, Mohamad‐Hani , Thakur, Ramna , Thirunavukkarasu, Sathish, Tiwari, Krishna, Truyen, Thien Tan Tri Tai , Tsai, Daniel Hsiang‐Te , Ullah, Atta , Unnikrishnan, Bhaskaran , Unsworth, Carolyn Anne, Usman, Jibrin Sammani , Valizadeh, Rohollah , Varghese, Joe , Vasankari, Tommi Juhani , Venketasubramanian, Narayanaswamy , Vervoort, Dominique , Villafañe, Jorge Hugo , Vinayak, Manish , Wafa, Hatem A , Walde, Mandaras Tariku, Willeit, Peter , Wolfe, Charles D.A. , Wolfe, Charles D. A., Yamagishi, Kazumasa , Yaribeygi, Habib , Yaya, Sanni , Ye, Pengpeng, Yonemoto, Naohiro , Yu, Chuanhua , Zastrozhin, Michael, Zhang, Chen , Zhang, Zhiqiang, Zielińska, Magdalena , Zyoud, Samer H. , Roth, Gregory A. , Feigin, Valery L. , Kulimbet, Mukhtar , Rahim, Fakher

Mayo Clinic

JAMA Neurology | May 23, 2025 | Volume: 82 | Issue: 8 | Pages: 765

10.1001/jamaneurol.2025.1522 | PMID 40406922 Get It

Importance Nontraumatic subarachnoid hemorrhage (SAH) represents the third most common stroke type with unique etiologies, risk factors, diagnostics, and treatments. Nevertheless, epidemiological studies often cluster SAH with other stroke types leaving its distinct burden estimates obscure. Objective To estimate the worldwide burden of SAH. Design, Setting, and Participants Based on the repeated cross-sectional Global Burden of Disease (GBD) 2021 study, the global burden of SAH in 1990 to 2021 was estimated. Moreover, the SAH burden was compared with other diseases, and its associations with 14 individual risk factors were investigated with available data in the GBD 2021 study. The GBD study included the burden estimates of nontraumatic SAH among all ages in 204 countries and territories between 1990 and 2021. Exposures SAH and 14 modifiable risk factors. Main Outcomes and Measures Absolute numbers and age-standardized rates with 95% uncertainty intervals (UIs) of SAH incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) as well as risk factor–specific population attributable fractions (PAFs). Results In 2021, the global age-standardized SAH incidence was 8.3 (95% UI, 7.3-9.5), prevalence was 92.2 (95% UI, 84.1-100.6), mortality was 4.2 (95% UI, 3.7-4.8), and DALY rate was 125.2 (95% UI, 110.5-142.6) per 100 000 people. The highest burden estimates were found in Latin America, the Caribbean, Oceania, and high-income Asia Pacific. Although the absolute number of SAH cases increased, especially in regions with a low sociodemographic index, all age-standardized burden rates decreased between 1990 and 2021: the incidence by 28.8% (95% UI, 25.7%-31.6%), prevalence by 16.1% (95% UI, 14.8%-17.7%), mortality by 56.1% (95% UI, 40.7%-64.3%), and DALY rate by 54.6% (95% UI, 42.8%-61.9%). Of 300 diseases, SAH ranked as the 36th most common cause of death and 59th most common cause of DALY in the world. Of all worldwide SAH-related DALYs, 71.6% (95% UI, 63.8%-78.6%) were associated with the 14 modeled risk factors of which high systolic blood pressure (population attributable fraction [PAF] = 51.6%; 95% UI, 38.0%-62.6%) and smoking (PAF = 14.4%; 95% UI, 12.4%-16.5%) had the highest attribution. Conclusions and Relevance Although the global age-standardized burden rates of SAH more than halved over the last 3 decades, SAH remained one of the most common cardiovascular and neurological causes of death and disabilities in the world, with increasing absolute case numbers. These findings suggest evidence for the potential health benefits of proactive public health planning and resource allocation toward the prevention of SAH.
Dysregulated Tricarboxylic Acid Cycle Metabolism Is Associated With Right Ventricular Maladaptation in Pulmonary Vascular Disease
Rosen, Darin , Kolb, Todd M. , Mathai, Stephen C. , Suresh, Karthik , D’Amico, Rachel, Hsu, Steven , Tedford, Ryan J. , Hemnes, Anna R. , Leopold, Jane A. , Horn, Evelyn M. , Erzurum, Serpil C. , Beck, Gerald J. , Hill, Nicholas S. , Farha, Samar , Grünig, Gabriele , Jellis, Christine , Kwon, Deborah , Park, Margaret , Xiao, L, Fessel, Jeffrey , Fu, Yongping , Postow, Lisa, Schmetter, Barry, Sutliff, R, Tian, Xuefei , Joseloff, Elizabeth, Wong, Brenda , Lawler, Laurie, Maron, B, Haythe, Jennifer , Krishnan, Udhay , Payne, David A., Bergman, Geoffrey , Bastert, K, Devereux, Richard B. , Kim, Ju Youn , Lohman, Julia, Racanelli, Alexandra C. , Ricketts, Michelle L., Sobol, Irina , Singh, Harsimran , Weinsaft, Jonathan W. , Mathai, S.C. , Carey, Kyle A. , Damico, Rachel L. , Enobun, Blessing , Sanni, Y, Brock, Heinz, Durst, Louise A., Head, Denise , Foley, Thomas A. , Gochanour, Benjamin R. , Halbach, H, Krowka, Michael J. , Menon, David K. , Park, Gyu Tae , Redfield, Margaret M. , Rohwer, Kristi, Williamson, Eric E. , Vanderpool, R, Yuan, Jason X.‐J. , Lim, C.S., Abidov, Aiden , Erickson, Harold , Cunningham, James M. , Pugh, Meredith E., Robbins, Ivan M. , Beck, Gerald J. , Aldred, Micheala A. , Asosingh, Kewal, Aylor, Joan, Beck, B, Borowski, A, Collart, Clara, Comhair, S.A.A., Drinko, Jeanne K., Finet, J. Emanuel , Flinn, Aisling M. , Geraci, M, Jacob, Miriam , Kanta, Alexandra, Larive, Brett , Lempel, Jason K. , Li, Minghui , MacKrell, J., Neumann, D., Nawabit, R, Odabashian, Jill, Olman, Mitchell A. , Park, M, Radeva, Milena , Renapurkar, R, Sharp, Jacqueline, Sherer, Stefan, WHW, Tang, Thomas, Jason , Wadih, K, Wells, Simon P. , Wilcox, Jane, Yu, S, Rounds, Sharon , Bull, Todd , Cadigan, John B., Rosen, Darin T , Rosenzweig, Erika B , Rischard, Franz P , Frantz, Robert P , Beck, Gerald J , Hill, Nicholas S , Barnard, John , Grunig, Gabriele , Jellis, Christine L , Kwon, Deborah H , Mehra, Reena , Park, Margaret M , Tang, W H Wilson , Hassoun, Paul M , Simpson, Catherine E , Hemnes, Anna , Horn, Evelyn M , Leopold, Jane A , Tedford, Ryan J , Mathai, Stephen C , Hsu, Steven , Rosenzweig, Erika B. , Rischard, Franz , Frantz, Robert P. , Barnard, John , Mehra, Reena , Tang, W.H. Wilson , Hassoun, Paul M. , Simpson, Catherine E. , Xiao, L, Fu, Y‐P, Gray, Michael P. , Wong, B, Waxman, Aaron B. , Systrom, David M , Brady, David J. , Chung, Wendy K. , Payne, D, Karas, Maria , Lohman, J, Ricketts, M, Balasubramanian, A, Carey, K, Gao, Lei , Halushka, Marc K. , Kass, David A. , Lin, Ting‐Tse , Mukherjee, Monica , Roth, J, Sanni, Y, Weiss, Robert E. , Zimmerman, Stefan L , Behfar, Atta , Borlaug, Barry A. , Brock, H Du, Head, D, Kane, Garvan C. , Sands, T. , Scott, Christopher G. , Terzic, André , Williamson, E, Garcia, Joe G. N. , Lim, C, Desai, Akshay S , Hansen, L, Newman, J, Brittain, Evan L , Cheng, Feixiong , Filippo, F Di, Flinn, A, Hu, Bo , Jaber, Wael A. , Kanta, A, Martín, Maite Velázquez , McCarthy, Kevin , Ramos, J, Wiggins, K, Willard, Belinda B. , Benza, Raymond L. , Fang, James C. , Gomberg‐Maitland, Mardi

Mayo Clinic

Journal of the American Heart Association | May 22, 2025 | Volume: 14 | Issue: 11 | Pages: No page available

10.1161/jaha.124.041127 | PMID 40401597 Get It

Background Right ventricular (RV) maladaptation to elevated pulmonary afterload is the primary determinant of outcomes in pulmonary artery (PA) hypertension; however, the pathobiological mechanisms underlying RV decompensation remain poorly understood. Methods We performed global untargeted metabolomics on plasma from 55 patients who underwent gold‐standard RV‐PA coupling measurements using multibeat pressure volume loop assessment in a single‐center cohort and from 1027 patients with coupling surrogate measurements in a larger multicenter cohort, the PVDOMICS (Pulmonary Vascular Disease Phenomics) study. Age and sex‐adjusted linear regression was performed to identify associations between metabolites and coupling metrics. Additionally, we performed a metabolic flux analysis using gene expression data from RV tissue in an independent cohort of 32 patients. Partial least squares–discriminant analysis was used to identify metabolites and reactions characteristic of the decompensated RV. Results RV‐PA coupling was negatively associated with tricarboxylic acid (TCA) cycle intermediate levels. Specifically, plasma α‐ketoglutarate and fumarate were significantly associated with all coupling metrics in both cohorts. Metabolic flux analysis indicated that decompensated RVs exhibited aberrant TCA cycle activity, including reduced acetyl coenzyme A entry and increased lactate elimination, suggesting a shift from the TCA cycle toward glycolysis at the RV tissue level. Conclusions We identify an association between circulating TCA cycle intermediate levels and RV‐PA uncoupling in 2 independent cohorts, and dysregulated TCA cycle metabolism in decompensated PA hypertension RVs, suggesting that aberrant TCA cycle metabolism could represent a hallmark of RV maladaptation in PA hypertension. Further study of this pathway is warranted to develop novel biomarkers of RV function or RV‐targeted therapies.
Novel Benchmark for Robotic Liver Resection – Bridging Tradition with Innovation
Pfister, Matthias , Ma, Yong , Yang, Guangchao, Li, Linqiang , Song, Xuan , Venezia, Raphael, Jeddou, Heithem , Floc’h, Bastien Le, Valverde, A. , Péru, N. , Pessaux, Patrick, Salloum, Chady , Blanc, P., Scatton, Olivier , Tzedakis, Stylianos , Fuks, David , Chaoui, Ismaël, Silva, Silvia Gomes da, Sobral, M., Centonze, Leonardo , Zhu, Zhu , Ratti, Francesca, Rompianesi, Gianluca , Shah, Jimmy, Wakabayashi, Taiga , Coelho, Fabrício Ferreira , Castillo‐Flores, Samy , Viti, Virginia, Boggi, Ugo , Han, Ho-Seong, Panaro, Fabrizio , Wakabayashi, Go, Ielpo, Benedetto , Mejia, Alejandro , Troisi, Roberto I., Choi, Gi Hong , Liu, Rong , Sucandy, Iswanto, Rela, Mohamed , D’Hondt, Mathieu , Bröering, Dieter C. , Clavien, Pierre‐Alain , Li, Zhihao , Dong, Yawen , Clavien, Pierre-Alain , Centonze, Leonardo , Li, Zhihao , Li, Zhihao, Raptis, Dimitri , Song, Xuan, Millet, Guillaume, Truant, Stéphanie , Venezia, Raphael, Pessaux, Patrick , Giannone, Fabio , Mabrut, Jean‐Yves , Mohkam, Kayvan , Cunha, António Sá , Roy, Bertrand Le , Goumard, Claire , Fuks, David , Rammohan, Ashwin , Silva, Silvia Gomes da, López‐López, Víctor , Ratti, Francesca, Marino, Rebecca , Müller, Philip C , Lee, Bo Ram , Kato, Yutaro , Polanco, Patricio Marcelo , Goh, Brian K P , Cheung, Tan To , Efanov, Mikhail G. , Machado, Marcel Cerqueira César , Herman, Paulo , Müller-Stich, Beat Peter , Starlinger, Patrick , Martinie, John B. , Aldrighetti, Luca , Chen, Guodong , Robles, R , Benedetto, Fabrizio Di , Marques, Hugo P. , Sucandy, Iswanto , Brustia, Raffaele , Soubrane, Olivier

Mayo Clinic

Annals of Surgery | May 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006759 | PMID 40391433 Get It

Objective: To establish benchmark cutoffs for robotic liver resection (R-LR), encompassing both major and minor resections, and to determine the impact of patient selection on outcomes. Background: R-LR is a key advancement in minimally invasive liver surgery but lacks standardized benchmarks, especially for minor resections. While guidelines endorse R-LR, its role in optimizing outcomes remains unclear. This study establishes the first benchmarks for R-LR, enabling comparisons across surgical modalities and refining patient selection. Methods: This retrospective, multicenter study analyzed consecutive adult patients undergoing R-LR at 30 international centers (2020–2023). Benchmark centers had an annual case volume of ≥15 R-LR. Benchmark criteria included ASA ≤2, no major comorbidities, no prior liver resections, and Child-Pugh A status. Benchmark cutoffs for 14 key outcomes were set at the 50th and 75th percentiles of median values across benchmark centers. Multivariable logistic regression identified predictors of textbook outcomes. Results: Eighteen high-volume centers contributed 4028 cases with 2632 (65.3%) meeting benchmark criteria. Malignancy was the indication in 29.6%, most commonly hepatocellular carcinoma followed by colorectal liver metastases. Major liver resection was performed in 42.6%. The distribution of Iwate difficulty scores was low (25.4%), intermediate (53.9%), advanced (15.9%), and expert (4.9%). Benchmark cutoffs were established for minor and major resection, and stratified by Iwate low (0-3), intermediate (4-6) and high (7-12): Open conversion (≤6.5% minor, ≤10.5% major), major complications within 90 days (≤5.2% minor, ≤16.7% major), R1 resection (≤9.2% minor, ≤6.7% major). Benchmark cases performed at low-volume centers were able to achieve outcomes within the corresponding benchmark cutoffs. In fact, patient selection reflected by the proportion of benchmark patients, rather than case volume, was associated with textbook outcomes. Conclusions: This study defines R-LR benchmarks, emphasizing patient selection over center volume for optimal outcomes. Benchmark cutoffs guide training and support the expansion of R-LR.
Musculoskeletal Findings of the Major League Baseball Combine: A Description of the “Normal” Prospective Professional Baseball Player
Erickson, Brandon J. , D’Angelo, John , Ma, Kevin , Casey, Helen, Papp, Derek F. , Lund, Pamela, Chalmers, Peter N. , Camp, Christopher L. , Chalmers, Peter N , Hebert, Liz, Potter, Hollis G.

Mayo Clinic

The American Journal of Sports Medicine | May 19, 2025 | Volume: 53 | Issue: 8 | Pages: 1826-1831

10.1177/03635465251339773 | PMID 40387901 Get It

Background: Major League Baseball (MLB) recently instituted a combine for their prospective players. Purpose/Hypothesis: The purpose of this study was to report initial epidemiological findings for both physical examination and imaging findings for the MLB Combine. It was hypothesized that most players would have no significant abnormal physical examination findings, but most would have abnormal findings on their shoulder and elbow magnetic resonance imaging (MRI) scans. Study Design: Descriptive epidemiology study. Methods: All players who attended the 2023 MLB Combine were included. History was taken and physical examination was performed by an MLB team physician, and MRI of the shoulder, elbow, cervical spine, and lumbar spine was performed on all players and read by 1 of 2 musculoskeletal radiologists. Physical examination notes and imaging reports were reviewed by the authors and recorded. Data were analyzed separately for pitchers and position players. Results: Overall, 219 players (112 pitchers [51%], 107 position players [49%]) were included. The mean age was 20.4 ± 1.5 years. The majority of players (95%) had no current pain or limitations; 54 players (25%) had a history of previous surgery. For pitchers, 18% underwent previous elbow surgery. With regard to MRI, >80% of pitchers had some abnormality within their ulnar collateral ligament (UCL), the majority of which was UCL scarring/remodeling. 70% of pitchers and 60% of position players had evidence of an olecranon osteophyte. Increased signal within the ulnar nerve was common in pitchers (40%) but rare in position players (4%). For the shoulder, 95% of pitchers and 93% of position players had some rotator cuff abnormality (often tendinosis within the supraspinatus and infraspinatus muscles). Also, 75% of pitchers had MRI evidence of a superior labrum anterior to posterior (SLAP) tear, while 24% of position players demonstrated this. Lumbar spine MRI showed that 47% of position players had a disk protrusion and 46% had a previous pars fracture. Conclusion: Most baseball players who participated in the 2023 MLB Combine had MRI evidence of rotator cuff abnormalities, and many showed evidence of an olecranon osteophyte. Eighteen percent of pitchers had a previous history of elbow surgery. The majority of pitchers had some abnormality within their UCL and evidence of a SLAP tear on MRI scans.